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ABSTRACT: The glial cell line-derived neurotrophic factor
(GDNF) family ligands (GFLs) support the survival and
functioning of various neuronal populations. Thus, they could
be attractive therapeutic agents against a multitude of
neurodegenerative diseases caused by progressive death of
GFLs responsive neurons. Small-molecule ligands BT13 and
BT18 show an effect on GDNF family receptor GFRα1 and
RET receptor tyrosine kinase RetA function. Thus, their
potential binding sites and interactions were explored in the
GDNF−GFRα1−RetA complex using molecular docking calculations as well as molecular dynamics (MD) simulations. Three
possible regions were examined: the interface between GDNF and GFRα1 (region A), the RetA interface with GFRα1 (region
B), and a possible allosteric site in GFRα1 (region C). The results obtained by the docking calculations and the MD simulations
indicate that the preferable binding occurs at the allosteric site. A less preferable binding site was detected on the RetA surface
interfacing GFRα1. In the membrane-bound state of RetA this can enable compounds BT13 and BT18 to act as direct RetA
agonists. The analysis of the MD simulations shows hydrogen bonds for BT13 and significant hydrophobic interactions with
GFRα1 for BT13 and BT18 at the allosteric site.
■ INTRODUCTION
The glial cell line-derived neurotrophic factor (GDNF) family
ligands (GFLs), which consist of GDNF, neurturin (NRTN),
artemin (ARTN), and persephin (PSPN), regulate the
development and maintenance of the nervous system.1 It has
been shown that GDNF protects and repairs brain dopamine-
producing neurons, which degenerate in Parkinson’s disease,
and motoneurons, which die in amyotrophic lateral sclerosis.
In addition, GDNF, NRTN, and ARTN support the survival
and regulate the differentiation of many peripheral neurons,
including sympathetic, parasympathetic, sensory, and enteric
neurons.2
The GFLs could therefore be attractive therapeutic agents
against a multitude of neurodegenerative diseases caused by
the extensive death of GFLs dependent neurons. Unfortu-
nately, the systemic delivery of GFLs into the central nervous
system neurons is complicated because of their poor
pharmacokinetic properties and bioavailability that are
common to large proteins. The delivery to the brain through
invasive approaches such as neurosurgery, viral vectors, or by
the use of encapsulated cells is also associated with multiple
obstacles. Consequently, small molecules that specifically
activate GFL receptors and that can be easily delivered to
the target neuronal populations would overcome most of these
problems.3
The first small molecules that mimic the effects of the
different GFLs have been recently reported.4−7 The high-
throughput screening of a library consisting of 18 400 drug-like
compounds had enabled identifying compound code-named
BT13 (N,N-diethyl-3-[4-[4-fluoro-2-(trifluoromethyl)-
benzoyl]piperazin-1-yl]-4-methoxybenzenesulfonamide) as a
compound that selectively targeted GFL receptor RET to
activate downstream signaling cascades.4,5 It was found that
BT13 activated luciferase in reporter-gene based systems in
GFRα1/RET, GFRα3/RET, and RET reporter cell lines with
comparable potency and efficacy at micromolar concentrations.
The further rational design lead to a compound BT18 ([4-[5-
[(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)sulfonyl]-2-
methoxyphenyl]piperazin-1-yl]-[4-fluoro-2-(trifluoromethyl)-
phenyl]methanone) with similar properties.6 Both compounds
demonstrated efficacy in rat model of experimental neuro-
pathy.5,6 However, the molecular mechanism of the RET
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activation by the small-molecule ligands BT13 and BT18
remained unclear.
Therefore, to elucidate this question and to enable a rational
design of more potent mimetics of GDNF, it would be highly
interesting to examine the possible interaction between these
known compounds with GDNF receptor complex consisting of
ligand-binding subunit GFRα1 and signal transducing module
transmembrane receptor tyrosine kinase RetA.
The aim of this study is therefore to explore the possible
binding sites and interactions of a small-molecule ligand BT135
and its derivative BT186 (Figure 1) with protein GFRα1 and
GFRα1−RetA interface. These compounds are known to have
an effect on GFRα1 and RetA functions.5,6 Molecular
dynamics (MD) simulations8−10 may help to elucidate the
binding site and time dynamics of interacting amino acid
residues and to extend the information obtained from previous
docking studies.
■ RESULTS AND DISCUSSION
Molecular Docking. Three possible regions in the
receptor GFRα1 and RetA were examined to find the potential
binding poses of compounds BT13 and BT18, using subunits
of the protein structure from the GDNF−GFRα1−RetA
complex (PDB code: 4UX8;11 see Computational Methods).
These included the interface between GDNF and GFRα1
(region A in Figure 2), the RetA interface with GFRα1 (region
B in Figure 2), and a possible allosteric site in GFRα1 (region
C in Figure 2). In region A, the small-molecule ligands would
directly mimic the effect by binding GDNF to the receptor
GFRα1. In region B that is located in the surface of RetA, the
effect of small compounds would be similar to GDNF-
activated GFRα1. Finally, there can be allosteric conforma-
tional changes in GFRα1 due to the binding of small-molecule
ligands and leading to the activation of the complex (region
C). Results from molecular docking indicate that the preferable
binding occurs at the allosteric site for both ligands (see Figure
3). The docking score to region C is −7.9 kcal/mol for
compound BT13, being 1.9 and 1.2 kcal/mol lower compared
to the binding score for regions A and B, respectively; and
−9.8 kcal/mol for compound BT18 to region C, being 3.4 and
2.3 kcal/mol lower than for the binding at other two regions.
It has been noted5,6 that both BT13 and BT18 also act as
RetA direct agonists. While the present calculations indicate
the preferable binding to the allosteric site at region C, the
binding site at RetA interface with GFRα1 (region B) may
become preferential in membrane-bound state of RetA, with
altered conformation as compared to the protein structure in
single-particle state used in the measuring of structure (PDB
code: 4UX8). The binding mode at the RetA interface with
GFRα1 (region B) involves hydrophobic interactions between
compound BT13 and residues of Thr120, Tyr122, and Tyr146
as well as stacking (π−π) interactions between the aromatic
rings of BT13 and Trp37 (Figure 3c). BT18 also makes
hydrophobic contacts to Tyr146 and Thr170 and π−π
interactions with Trp37 (Figure 3d).
The binding mode at the allosteric site (region C) involves
hydrogen bonding between the sulfonyl group of the ligand
BT13 and the ammonium group of Lys327 of the receptor
GFRα1, in addition to hydrophobic contacts with Asn40,
Phe41, Gln247, Lys251, Leu260, Ala261, and Phe328 (Figure
3e). The ligand BT18 is hydrogen bonded by a methoxy group
to the amine group of Asn40 of GFRα1 and has additional
hydrophobic interactions with residues of Phe41, Gln247,
Lys251, Leu260, Ala261, Phe264, Asp324, Lys327, and Phe328
(Figure 3f).
To verify our results obtained by using protein structure of
GDNF−GFRα1−RetA complex (PDB code: 4UX8), calcu-
lations using crystal structure of the GDNF−GFRα1 complex
(PDB code: 3FUB;12 see Computational Methods) were
carried out as a control. The GFRα1 parts of both structures
overlap very well (Figure 4a). The binding modes of ligands
BT13 and BT18 are almost identical at the GDNF−GFRα1
interface (Figure 4b,c) but somewhat different at the allosteric
site (Figure 4d,e), although the interacting residues of GFRα1
are mostly the same. A possible reason is discussed below, in
the next section. All results of molecular docking for BT13 and
BT18 are presented in the Supporting Information in Table S1.
MD with Desmond Simulation Package. The docking
calculations were followed by MD simulations using Desmond
package on the three potential binding sites at regions A, B,
and C, respectively. The root mean square deviation (rmsd) of
the atomic positions behavior is notably large for the regions
corresponding to the GDNF−GFRα1 interface (region A) and
RetA (region B) (see Figure S1a−d). Smaller rmsd variations
show the stability of the ligand binding. Notably, in the
simulation of compounds BT13 and BT18 binding to the
region C that corresponds to the allosteric site on the receptor
GFRα1, there is no large variation of this parameter (Figure
Figure 1. Chemical structures of small-molecule ligands BT13 and
BT18.
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S1e,f). Thus, in accordance with the molecular docking results,
this binding site is preferable.
The location of the binding modes of compounds BT13 and
BT18 were also confirmed by the counterpart MD modeling.
The results at the allosteric site are however somewhat
different from that obtained in molecular docking calculations.
There is significant hydrophobic interaction between the
ligand BT13 and the receptor GFRα1 around protein residues
Lys251 to Phe264 (see the protein−ligand contacts diagram in
Figure 5a). Hydrogen bonding is involved in interactions with
the residues Phe41 and Thr265. Notably, the interactions over
the water molecule bridges are rather significant, for example,
the water-assisted ionic contact to Lys327, which was also
shown by the docking results. The ligand BT18 shows a very
strong hydrophobic interaction with the residue Phe41 (being
in hydrophobic contact almost 100% of MD simulation time)
besides other hydrophobic interactions around protein
residues Leu244 to Phe264 (see the protein−ligand contacts
diagram in Figure 5b). The water-assisted bindings are also
represented. The binding modes of the ligands at the regions A
and B are quite similar to the docking calculations and are
given in the Supporting Information (Figures S2 and S3,
respectively).
MD simulations were also repeated with the crystal structure
of GDNF−GFRα1 complex (3FUB12) for BT13 and BT18
(see the corresponding rmsd of the atomic positions for
ligands and protein in Figure S4, protein−ligand contacts at
the GDNF−GFRα1 interface in Figure S5, and at the allosteric
site in Figure 6). The results obtained for binding at the
GDNF−GFRα1 interface are similar, however, somewhat
different at the allosteric site for two protein structures used
in this study (4UX8 and 3FUB). In fact, GFRα1 consists of
domains D1, D2, and D3, whereas D1 is not needed for GDNF
binding,12 it binds to RetA in the full structure in 4UX8.11
According to our calculations, D1 has an effect on protein−
ligand interactions at the allosteric site as well as it would be
significant in determining the signaling-related conformational
changes. Anyway, no interaction between RET and GDNF or
GFRα1 co-receptor individually was detectable.11
To specify the nature of the protein−ligand interactions, the
molecular mechanics/Poisson−Boltzmann surface area (MM/
PBSA)13 binding energy calculations were carried out using
data from MD simulations. In MM/PBSA, the free energy of a
state (ligand, protein, or complex) is estimated from the
following sum:
G E E E G G TSbnd el vdW pol np= + + + + − (1)
Figure 3. Calculated binding modes of the protein-ligand complexes: (a) GFRα1−BT13 at the GDNF−GFRα1 interface, region A (ΔGbind = −6.0
kcal/mol); (b) GFRα1-BT18 at the GDNF−GFRα1 interface, region A (ΔGbind = −6.4 kcal/mol); (c) RetA−BT13 at the RetA−GFRα1 interface,
region B (ΔGbind = −6.7 kcal/mol); (d) RetA-BT18 at the RetA−GFRα1 interface, region B (ΔGbind = −7.5 kcal/mol); (e) GFRα1−BT13 at the
allosteric site, region C (ΔGbind = −7.9 kcal/mol); and (f) GFRα1−BT18 at the allosteric site, region C (ΔGbind = −9.8 kcal/mol). The amino acid
residues of protein (PDB code: 4UX8) are colored as gray (carbon), blue (nitrogen), red (oxygen), and white (hydrogen). Intermolecular
hydrogen bonds are shown by dashed lines.
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where the first three terms are standard MM energy terms
from bonded (bond, angle, and dihedral), electrostatic, and
van der Waals interactions, respectively. Gpol and Gnp are the
polar and nonpolar contributions to the solvation free energies,
respectively. Gpol is typically obtained by solving the Poisson−
Boltzmann equation or by using the generalized Born (GB)
model (giving the MM/GBSA approach), whereas the
nonpolar term is estimated from a linear relation to the
solvent accessible surface area. The last term in the above
equation is the absolute temperature, T, multiplied by the
entropy, S, estimated by a normal-mode analysis of the
vibrational frequencies. The results for binding energy states14
at different sites are given in Table 1. The allosteric site on the
receptor GFRα1 is predicted to be notably more preferable for
binding the small-molecule ligands. The corresponding binding
free energy is −50.9 kcal/mol for ligand BT13, being 3.4 and
2.4 kcal/mol lower compared with the binding energy for
regions A and B, respectively; −55.7 kcal/mol for ligand BT18,
being 5.0 and 5.9 kcal/mol lower than that for the other
potential binding regions.
MD with AMBER Package. To check if the binding of
BT13 was stable at site C with a different program and force
field, additional AMBER simulations on compound BT13 were
carried out at the allosteric site of GFRα1, using the crystal
structure of domain 3 of GFRα1 (PDB code: 1Q8D15). The
simulations were stable throughout the whole trajectories, as
shown by small variation of energy, volume, and pressure
through time. The rmsd of the ligand seen in Figure S6 shows
a stable binding interaction with small deviations from the
initial position. The rmsd of the alpha carbons of the protein
also shows stability in the protein structure shown in Figure S7.
In this respect, simulation with AMBER reproduced the stable
binding and complex formation at site C.
Analysis of the trajectories showed that the loop of residues
Pro32 to Cys40 was the most mobile part of the protein, with
the loop closing in on top of ligand BT13. Among the most
mobile residues in this loop were Arg35 (Arg272 in the full
structure in 4UX8) with an rmsd per residue of 7.9 Å as shown
in Table S2, Figure 7, and Figure S8, along with the edge
residue Tyr17 (Tyr254 in the full structure in 4UX8) of 9.3 Å,
as compared to the average value of 6.4 Å for all protein
residues and the ligand. Important to notice is that Arg272 and
Tyr254 are precisely the residues that make contact between
GFRα1 and RetA in structure 4UX8 that contains these
proteins in addition to GDNF in a ternary complex. Also
important to note is that residue 105 corresponding to ligand
BT13, had a below average rmsd of 5.9 Å, which again shows
stability in the binding interaction. Residues 106 and 107 also
had high rmsd’s as is to be expected because they are free
sodium ions in solution.
The closure of the loop brings into contact protein groups
Arg272 and the ligand sulfonamide and aromatic atoms, as
seen in Figure 8 and Table 2. In addition, the fluorine and
amide carbonyl groups of the ligand make stable hydrogen
bonds with Gln10 (Gln247 in 4UX8) in the protein, as shown
in Figure 8 and Table 2. The AMBER MD results are in
agreement with the Desmond MD results, as these residues are
also the most important contributors to the binding of BT13 in
the Desmond MD simulations.
■ CONCLUSIONS
The binding pose of compounds BT13 and BT18 to the
allosteric site of GFRα1 seems to be stable throughout several
long enough MD simulation times, maintaining complexation
and hydrogen bonding for BT13 as well as hydrophobic
contacts with preferred partners on the protein for BT13 and
BT18. Given that the loop in GFRα1 has strong interactions
with the ligand BT13 and is also in close contact to its partner
RetA (Arg272 in GFRα1; Tyr76, Tyr122, and Tyr146 in
RetA) as well as the GFRα1 edge residue Tyr254 being in
close contact to Lys75 and Glu77 in RetA, the conformational
changes seen in the protein in the GFRα1−BT13 complex may
affect binding to RetA, and in turn, induce conformational
changes in RetA, which may lead to its activation.
However, as noted above, both ligands also act as RetA
direct agonists. Thus, apparently the binding site at RetA
interface with GFRα1 (region B) becomes preferential in
membrane-bound state of RetA like that has different
conformation as compared to the protein structure in single-
particle state used in this modeling work. This enables
compounds BT13 and BT18 to act as direct agonists of RetA.
However, the binding of the studied compounds to either
component of GDNF receptor complex (co-receptor or RetA)
is predominantly originating from the rather loose and
nonspecific hydrophobic and van der Waals interactions and
the favored binding site is rather flat. Thus, it might not be easy
Figure 4. Comparison of the binding of compounds BT13 and BT18
to protein structures 4UX8 (green) and 3FUB (white). (a) 4UX8 and
3FUB; (b) compound BT13 at the GDNF−GFRα1 interface, region
A; (c) compound BT18 at the GDNF−GFRα1 interface, region A;
(d) compound BT13 at the allosteric site of GFRα1, region C; (e)
compound BT18 at the allosteric site of GFRα1, region C. In each
graph (b−e), the ligand conformation with protein structure 3FUB is
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Figure 5. Desmond MD calculated protein−ligand contacts at the allosteric site, region C: (a) GFRα1−BT13; (b) GFRα1−BT18. Protein code:
4UX8.
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to increase the binding efficiency of the ligands and minor
modifications in the ligand structure can lead to substantial
changes in their binding mode and inactivation. Nevertheless,
the present elucidation of the detailed mechanism of
interaction between the known active compounds and the
GFRα1 and RetA receptor complex enables further rational
design of highly effective GDNF mimicking small molecules.
■ COMPUTATIONAL METHODS
Small-Molecule Ligands and Target. The structure of
ligand BT13 had been obtained through a high-throughput
screening procedure;5 compound BT18 is a further develop-
ment of this structure.6 We proceeded from a protein and two
crystal structures on the GDNF−GFRα1 complex downloaded
from Protein Data Bank (PDB).16 The hybrid structural model
of reconstituted mammalian GDNF−GFRα1−RetA complex
(PDB code: 4UX8) had been derived from electron
microscopy (EM) and low-angle X-ray scattering (SAXS)
data with a resolution 24.0 Å.11 Combination of cryo-EM and
SAXS can be a suitable method to study such kind of big
protein complexes. This protein structure was previously also
exploited for homology modeling, MD simulations, and
molecular docking studies.17 The complex consists of chain
A and chain B (RetA extracellular domain; residues 29−508),
chain C and chain E (GFRα1 with domains D1−D3; residues
6−348), and chain D and chain F (GDNF; residues 42−134).
The crystal structure of GDNF−GFRα1 complex (PDB code:
3FUB) contains two chains of GFRα1 (chain A, residues 150−
348; chain C, residues 150−348) and two chains of GDNF
(chain B, residues 40−134; chain D, residues 32−134) as
measured by X-ray diffraction with a resolution 2.35 Å.12
Another crystal structure (PDB code: 1Q8D) containing the
GDNF family co-receptor alpha 1 domain 3 has been reported
as measured by X-ray diffraction with a resolution 1.80 Å15 and
consists of chain A (GFRα1; residues 239−346). Protein
structures were prepared (including energy minimization) and
hydrogen atoms were added using the Protein Preparation
Wizard18 in the Schrödinger Maestro19 software, assuming a
pH of 7.4. Possible hydrogen bond interactions, the solvent
exposure, and the local surroundings of the histidine residues
by visual inspection were also analyzed. All water molecules
were kept in the calculations of MD simulation. Water
molecules were removed from the protein structure of
GDNF−GFRα1−RetA complex and the crystal structure of
GDNF−GFRα1 complex for the docking study.
Molecular Docking. The binding poses of BT13 and
BT18 on the GDNF−GFRα1−RetA complex (PDB code:
4UX8) were obtained by docking calculations using AutoDock
Vina 1.1.2.20 The ligands were optimized before molecular
docking by the Ligand Preparation21 (OPLS_2005 force field)
in the Schrödinger Maestro19 software. The active binding site
on GFRα1 (selected residues of domain D2 in chain C),
Table 1. Binding Free Energies (in kcal/mol) of the Protein−Ligand Complexes at Different Sites Calculated Using the MM/
GBSA Method
BT13 BT18
energy term region A region B region C region A region B region C
ΔEH‑bnd −0.90 −0.01 −0.61 −2.58 −0.10 −0.77
ΔEcovalent‑bnd 2.49 6.87 3.43 6.57 4.85 10.35
ΔEel 9.81 27.74 28.07 20.34 23.41 28.56
ΔEvdW −30.15 −34.45 −45.43 −28.89 −37.35 −53.70
ΔEπ−π −0.39 −5.57 −0.30 −0.32 −2.95 −0.79
ΔGpol −5.63 −14.93 −13.41 −11.64 −11.41 −13.56
ΔGnp −22.76 −28.12 −22.64 −34.20 −26.29 −25.79
ΔGbind −47.53 −48.47 −50.89 −50.73 −49.84 −55.70
Figure 7. Complex of GDNF (white and yellow) + GFRα1
(chocolate -4UX8- and blue -1Q8D-) + RetA (green) + ligand
BT13 (in sticks and cyan), showing the loop with most movement
(shown in red quadrate) and contacts with RetA.
Figure 8. Ligand BT13 (backbone in white) in complex with protein
GFRα1 after (a) 1 and (b) 8 ns of explicit water, periodic box
AMBER MD simulations. Intermolecular hydrogen bonds are shown
as yellow dashes. Gln10 corresponds to Gln247 and Arg35
corresponds to Arg272 in Desmond MD runs.
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named region A, was obtained by the removal of GDNF (chain
D). The active binding site on RetA (selected residues of
cadherin-like domains 1 and 2 in chain A), named region B,
was obtained by the removal of GFRα1 (chain C). Both
regions were surrounded with a grid box sized 20 × 20 × 20
points with a spacing of 1.000 Å. The allosteric binding site in
the middle of GFRα1 (selected residues of domains D1−D3 in
chain C), named region C, was surrounded with a grid box
sized 30 × 40 × 20 points with a spacing of 1.000 Å. The
settings used for the iterated local search global optimizer
based on mutation and local optimization steps accepted or
rejected with a Metropolis criterion in Vina were nine modes,
one central processing unit, and an energy range of 1 kcal/mol.
Other settings were used as default. AutoDockTools (ADT)22
1.5.6 was used to identify the binding sites as well as to analyze
interactions between protein and ligands. The same procedure
and the same parameters, that is, coordinates and size of grid
box, were also used in case of the GDNF−GFRα1 complex
(PDB code: 3FUB).
Molecular Dynamics. The MD simulations were carried
out using Desmond simulation package of Schrödinger LLC.23
The NPT ensemble with the temperature 300 K and a pressure
1 bar was applied in all runs. The simulation length was 50 ns
with a relaxation time 1 ps for the ligands BT13 and BT18.
The OPLS_2005 force field parameters were used in all
simulations.24 The long-range electrostatic interactions were
calculated using the particle mesh Ewald method.25 The cutoff
radius in Coulomb interactions was 9.0 Å. The water molecules
were explicitly described using the simple point charge
model.26 The Martyna−Tuckerman−Klein chain coupling
scheme27 with a coupling constant of 2.0 ps was used for the
pressure control and the Nose−́Hoover chain coupling
scheme27 for the temperature control. Nonbonded forces
were calculated using an r-RESPA integrator where the short-
range forces were updated every step and the long-range forces
were updated every three steps. The trajectories were saved at
4.8 ps intervals for analysis. The behavior and interactions
between the ligands and protein were analyzed using the
Simulation Interaction Diagram tool implemented in Desmond
MD package. The stability of MD simulations was monitored
by looking on the rmsd of the ligand and protein atom
positions in time.
The AMBER 14 package28 with AMBER force field ff9929
was also used to minimize, add counterions, solvate,
equilibrate, and run periodic box, explicit water (TIP4P)
MD simulations for ligand BT13. The structure of molecule
BT13 was optimized using the density functional theory
B3LYP method30 with 6-31G basis set and parameters set to
the GAFF force field. The protein−ligand−water system was
allowed to move freely. Simulations were 10 independent runs
with different random initial velocities, each of them 10 ns
long, using a 0.001 ps (1 fs) timestep. These are multiple
molecular dynamics simulations, which are widely accepted9,31
and can sample enough conformational space as longer, single
trajectory simulations. The data analysis was carried out with
the cpptraj program (AMBER Tools distribution).28
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